H

HeartFlow

Listed

HeartFlow offers a non-invasive AI-powered clinical decision support tool that analyzes CT scans to assess coronary artery disease.

About

HeartFlow offers a non-invasive AI-powered clinical decision support tool that analyzes CT scans to assess coronary artery disease.

Detailed overview

Overview

HeartFlow provides AI-powered analysis of coronary computed tomography angiography (CCTA) scans to aid in the diagnosis and management of coronary artery disease (CAD). Their platform, HeartFlow One, transforms CCTA data into personalized 3D models of the heart, offering insights into anatomy, physiology, and plaque characteristics. The company aims to help clinicians make informed decisions for patient treatment pathways.

Key Features

  • Roadmap Analysis — Improves efficiency and consistency in reading CCTA scans by providing an intuitive overview of coronary lesions.
  • FFRCT Analysis — Assesses blood flow anywhere in the coronary tree to determine the benefit of revascularization non-invasively.
  • Plaque Analysis — Quantifies and characterizes plaque to inform risk assessment and disease management.
  • Integrated Workflow — Delivers analysis directly into Picture Archiving and Communication Systems (PACS) and Electronic Medical Records (EMR) for streamlined care.
  • Clinical Support — Offers resources for building and scaling CCTA programs, including operational, technical, and financial assistance.

Who It's For

HeartFlow is designed for cardiologists, radiologists, and healthcare institutions involved in the diagnosis and management of coronary artery disease. It targets practices and hospitals seeking to enhance the accuracy and efficiency of CCTA interpretation and personalize patient treatment plans. The platform supports medical professionals aiming to integrate advanced AI analytics into their cardiovascular care pathways.

Notable Strengths

HeartFlow demonstrates a strong evidence base with over 625 peer-reviewed publications and experience with over 650,000 treated patients. The platform's FFRCT Analysis has shown a 69% decrease in unnecessary invasive coronary angiographies, indicating its effectiveness in guiding revascularization decisions. Its integration capabilities allow for seamless delivery of analysis into existing PACS and EMR systems, supporting efficient clinical workflows.

Website link is available on the Verified plan